A targeted drug delivery nanosystem to hepatocellular carcinoma

Hepatocellular Carcinoma (HCC) is one of the major frequent cause of cancer-related mortality worldwide. Combination of different chemotherapeutics drugs may offer advantages for the treatment of HCC. Targeted hepatocellular carcinoma therapy was carried out to improve the efficacy of liver cancer treatment. The purpose of this study was to design an N-acetylgalactosamine (NAcGal) modified and pH sensitive doxorubicin (DOX) prodrug (NAcGal-DOX) for the construction of lipid nanoparticles (LNPs)

Author(s): Henrique Faneca

Abstract | PDF

Share This Article